Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. (NASDAQ: AXGN) is a medical technology company focused on peripheral nerve repair, regeneration, and restoration of function. The AXGN news feed on this page aggregates company announcements, earnings releases, regulatory updates, and other disclosures related to its nerve repair portfolio and corporate activities.
Recent Axogen news has highlighted revenue growth, gross margin trends, and updated financial guidance, as well as developments in reimbursement coverage for nerve repair procedures using allografts and synthetic conduits. Earnings releases and accompanying conference calls provide details on revenue by quarter, profitability metrics, cash and investment balances, and management’s commentary on market development and commercial execution across extremities, oral and maxillofacial, head and neck, and breast reconstruction markets.
Regulatory milestones are a key theme in AXGN news. The company has reported FDA acceptance and subsequent approval of its Biologics License Application for Avance (acellular nerve allograft-arwx), including information on the Prescription Drug User Fee Act (PDUFA) review timeline, accelerated approval indications, and anticipated commercial availability under the biologic framework. Updates on professional society position statements and clinical practice guidelines recognizing nerve allograft as a standard medical practice option for peripheral nerve defects also appear in company communications.
Investors and observers can also find notices about Axogen’s participation in healthcare and investor conferences, where management presents the company’s strategy and meets with institutional investors. By following AXGN news here, readers can monitor financial results, regulatory progress, reimbursement developments, and corporate events that shape Axogen’s peripheral nerve repair business over time.
Axogen (NASDAQ: AXGN) will participate in the 75th Annual Meeting of the American Society for Surgery of the Hand from October 1-3, 2020. Key presentations will highlight the clinical and economic benefits of Avance Nerve Graft compared to traditional nerve autografts. Clinical data from the RANGER® Registry shows comparable outcomes for sensory and motor nerve injuries. Additionally, a cost evaluation confirms Avance's procedural costs are competitive. Axogen will also host a virtual symposium, Nerve Repair Live, on September 29, featuring live surgical demonstrations.
Axogen (NASDAQ: AXGN) announced that Karen Zaderej, chairman, CEO, and president, will present at the Cantor Virtual Global Healthcare Conference on September 16, 2020, at 1:20 p.m. ET. The presentation will be available via live webcast on the company's Investors page.
Axogen is a leader in developing surgical solutions for peripheral nerve damage, offering products like Avance® Nerve Graft and Axoguard® Nerve Protector to enhance recovery and improve patients' quality of life.
Axogen, a leader in surgical solutions for peripheral nerve repair, announced that CEO Karen Zaderej will present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 9:00 a.m. ET. The presentation will be available via live webcast on Axogen's investor page, with a replay accessible for 90 days. Axogen specializes in innovative technologies for nerve regeneration, offering a range of products including Avance Nerve Graft and Axoguard products to assist in nerve repair and protection. The company is committed to improving patient outcomes in nerve function restoration.
Axogen, Inc. (NASDAQ: AXGN) will release its second quarter 2020 financial results on August 5, 2020, post-market. The company's management will hold a conference call and webcast at 4:30 p.m. ET to discuss these results. Axogen is recognized for its innovative surgical solutions for peripheral nerve damage, including its portfolio of products like Avance® Nerve Graft and Axoguard® series. Investors can join the call by phone or through the company's website. A replay will be available after the call.
Axogen, Inc. (NASDAQ: AXGN) announced a financing agreement with Oberland Capital, allowing for up to $75 million in tranches. The first tranche of $35 million was drawn on June 30, 2020. Preliminary revenue for Q2 2020 is estimated at $21 million, down 21% from the previous year. The financing will support expansion, including a new biologic processing center. The CEO noted a regional recovery in nerve repair procedures but cautioned that COVID-19 continues to impact surgical volume, leading to a cautious revenue outlook for the remainder of the year.
Axogen, a leader in innovative surgical solutions for peripheral nerve repair, announced Brad Ottinger as the new General Counsel and Chief Compliance Officer effective June 1, 2020. Ottinger brings over 25 years of experience in legal and compliance roles within the medical device sector, previously serving at MicroPort Orthopedics. He succeeds Greg Freitag, who retired but will remain on the Board of Directors as Special Counsel. CEO Karen Zaderej expressed confidence in Ottinger's expertise, highlighting its importance for the company's growth and compliance efforts in the nerve repair market.
Axogen, Inc. (NASDAQ: AXGN) announced that Karen Zaderej, CEO and chairman, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 2:00 p.m. ET. The presentation will be available via a live webcast on the company’s Investors page and can be replayed for 90 days after the event. Axogen focuses on innovative surgical solutions for peripheral nerve damage, with a portfolio that includes products like Avance® Nerve Graft and Axoguard® Nerve Protector, aimed at restoring nerve function and improving patient quality of life.
Axogen, Inc. (NASDAQ: AXGN) reported Q1 2020 net revenue of $24.3 million, a 4% increase from Q1 2019. However, gross margin declined to 80.1%. The company posted a net loss of $8.2 million or $0.21 per share, compared to a loss of $9.5 million in the same quarter last year. Active accounts rose by 13% to 825. Due to COVID-19, the company suspended its 2020 guidance, foreseeing reduced revenues. Additionally, Axogen returned a $7.8 million PPP loan amid changing eligibility standards. A class action lawsuit was dismissed, and cost-cutting measures were implemented.